• PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer 

      Tsoukalas N., Kiakou M., Tsapakidis K., Tolia M., Aravantinou-Fatorou E., Baxevanos P., Kyrgias G., Theocharis S. (2019)
      The integration of immunotherapeutic agents in the treatment of non-small cell lung cancer (NSCLC) has revolutionized the approach of the prevalent type of lung cancer. Although PD-1 and its ligands (PD-L1 and PD-L2) are ...